BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback